PMID- 8627287 OWN - NLM STAT- MEDLINE DCOM- 19960625 LR - 20190630 IS - 0022-3042 (Print) IS - 0022-3042 (Linking) VI - 66 IP - 4 DP - 1996 Apr TI - Characterization of the responses of Purkinje cells to neurotrophin treatment. PG - 1362-73 AB - The ability of the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) to promote neuronal survival and phenotypic differentiation was examined in dissociated cultures from embryonic day 16 rat cerebellum. BDNF treatment increased the survival of neuron-specific enolase-immunopositve cells by 250 and 400% after 8 and 10 days in culture, respectively. A subpopulation of these neurons, the Purkinje cells, identified by calbindin staining, was increased to an equivalent extent, approximately 200%, following BDNF, NT-4/5 or NT-3 treatment. The number of GABAergic neurons, identified by GABA immunoreactivity, was greatly increased by treatment with BDNF (470%) and moderately by NT-4/5 (46%), whereas NT-3 was without effect. NGF failed to increase the number of either Purkinje cells or GABAergic neurons. Addition of BDNF within 48 h of cell plating was required to obtain a maximal increase in Purkinje cell number after 8 days. In contrast, the NT-3 responses were nearly equivalent even if treatment was delayed for 96 h after plating. BDNF, NT-4/5, and NT-3, but not NGF, induced the rapid expression of the immediate early gene c-fos. Immunocytochemical double-labeling with antibodies to c-fos and calbindin was used to identify Purkinje cells that responded to neurotrophin treatment by induction of c-fos. After 4 days in vitro, both BDNF and NT-3 induced the formation of c-fos protein in calbindin-immunopositive neurons, whereas NT-4/5 did not. The latter results suggest that although BDNF and NT-4/5 have been shown to act through a common receptor, TrkB, it appears that the effects of BDNF and NT4/5 are not identical. FAU - Larkfors, L AU - Larkfors L AD - Regeneron Pharmaceuticals, Tarrytown, New York, USA. FAU - Lindsay, R M AU - Lindsay RM FAU - Alderson, R F AU - Alderson RF LA - eng PT - Journal Article PL - England TA - J Neurochem JT - Journal of neurochemistry JID - 2985190R RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Calbindins) RN - 0 (Nerve Growth Factors) RN - 0 (Nerve Tissue Proteins) RN - 0 (Neurotrophin 3) RN - 0 (Proto-Oncogene Proteins c-fos) RN - 0 (RNA, Messenger) RN - 0 (Receptor, Ciliary Neurotrophic Factor) RN - 0 (Receptors, Nerve Growth Factor) RN - 0 (S100 Calcium Binding Protein G) RN - 145172-44-7 (neurotrophin 5) RN - 56-12-2 (gamma-Aminobutyric Acid) RN - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases) RN - EC 2.7.10.1 (Receptor, trkC) RN - P658DCA9XD (neurotrophin 4) SB - IM MH - Animals MH - Antibody Specificity MH - Blotting, Northern MH - Brain-Derived Neurotrophic Factor MH - Calbindins MH - Cell Count/drug effects MH - Cells, Cultured/cytology/drug effects MH - Cerebellum/cytology MH - Female MH - Humans MH - Immunohistochemistry MH - Nerve Growth Factors/*pharmacology MH - Nerve Tissue Proteins/*pharmacology MH - Neurons/chemistry/cytology/drug effects MH - Neurotrophin 3 MH - Pregnancy MH - Proto-Oncogene Proteins c-fos/analysis/drug effects/immunology MH - Purkinje Cells/chemistry/cytology/*drug effects MH - RNA, Messenger/analysis MH - Rats MH - Rats, Sprague-Dawley MH - Receptor Protein-Tyrosine Kinases/genetics MH - Receptor, Ciliary Neurotrophic Factor MH - Receptor, trkC MH - Receptors, Nerve Growth Factor/genetics MH - S100 Calcium Binding Protein G/analysis/drug effects/immunology MH - Time Factors MH - gamma-Aminobutyric Acid/physiology EDAT- 1996/04/01 00:00 MHDA- 1996/04/01 00:01 CRDT- 1996/04/01 00:00 PHST- 1996/04/01 00:00 [pubmed] PHST- 1996/04/01 00:01 [medline] PHST- 1996/04/01 00:00 [entrez] AID - 10.1046/j.1471-4159.1996.66041362.x [doi] PST - ppublish SO - J Neurochem. 1996 Apr;66(4):1362-73. doi: 10.1046/j.1471-4159.1996.66041362.x.